1-4 of 4
Alfred Rademaker, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Study of Sequential Pembrolizumab (PEM) Followed By AVD for Frontline Treatment of Classical Hodgkin Lymphoma (CHL): Quantifying Response Following PEM Monotherapy with FDG-PET-Derived Metabolic Tumor Volume and Total Lesion Glycolysis

Hatice Savas, MD, Pamela Allen, MDMSc, Andrew M. Evens, DO, MSc, Barbara Pro, MD, Gary Dillehay, MD, Alfred Rademaker, PhD, Brett Alan Palmer, BS, Ranjana Advani, MD, Leo I. Gordon, MD, Jane N. Winter, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1651.
https://doi.org/10.1182/blood-2018-99-113836
Published: 2018
Journal Articles

Administration of All-Trans Retinoic Acid (ATRA) to Newly Diagnosed Patients (pts) with Acute Promyelocytic Leukemia (APL) Is Delayed Even At Experienced Centers and Associated with An Increased Early Death Rate (EDR): A Retrospective Analysis of 205 Pts

Jessica K. Altman, MD, Alfred Rademaker, PhD, Elizabeth Cull, MD, Bing Bing Weitner, MS, Yishai Ofran, MD, Todd L. Rosenblat, MD, Augustin Haidau, MD, Jae H. Park, MD, Sharona Ram, MD, James Orsini, MD, Sonia Sandhu, MD, Rose Catchatourian, MD, Steven M. Trifilio, RPh, Nelly G. Adel, PharmD, BCOP, BCPS, Olga Frankfurt, MD, George Mallios, MD, Tony Deblasio, MS, Joseph G. Jurcic, MD, Stephen Nimer, MD, Jacob M. Rowe, MD, Dan Douer, MD, Martin S. Tallman, MD
Journal: Blood
Blood (2011) 118 (21): 942.
https://doi.org/10.1182/blood.V118.21.942.942
Published: 2011
Journal Articles

Alemtuzumab (Campath-1H) in Patients with Erythrodermic Cutaneous T-Cell Lymphoma (E-CTCL): The Northwestern University Experience.

Christiane Querfeld, MD, Steven T. Rosen, MD, Joan Guitart, MD, Brenda Martone, RN, MSN, Alfred Rademaker, PhD, Timothy M. Kuzel, MD
Journal: Blood
Blood (2006) 108 (11): 2732.
https://doi.org/10.1182/blood.V108.11.2732.2732
Published: 2006
Journal Articles

Autologous Stem Cell Transplantation (AuSCT) with Total Lymphoid Irradiation (TLI) and High-Dose Chemotherapy (CT) Results in High Survival Rates for “Poor-Prognosis” Relapsed/Refractory (R/R) Hodgkin’s Disease (HD): Multivariate Analysis of Outcome Shows Marked Benefit for TLI in a Prospective Phase I/II Trial.

Andrew M. Evens, DO, MS, Alfred Rademaker, PhD, Bharat B. Mittal, MD, Jessica K. Altman, MD, David Patton, BS, Lynne Kaminer, MD, Seema Singhal, MD, Daina Variakojis, MD, Stephanie Williams, MD, Martin S. Tallman, MD, Jayesh N. Mehta, MD, Jane N. Winter, MD, Leo I. Gordon, MD
Journal: Blood
Blood (2005) 106 (11): 2080.
https://doi.org/10.1182/blood.V106.11.2080.2080
Published: 2005